On August 7, Tempus AI rose 6.07% in regular trading, trading at $49.85/share, with turnover of $43.65 million.

The stock's advance came amid a broad rally in AI application software names, with peers such as Doximity surging nearly 80%, Atlassian jumping over 35%, and Twilio gaining more than 23%. Tempus AI's rise was further supported by its recently reported Q2 results, which significantly exceeded expectations. The company posted an adjusted loss of $0.04 per share versus the consensus estimate of a $0.14 loss, representing a 71.43% beat. Revenue came in at $382.5 million, above the $379.7 million estimate, marking a 21.6% year-over-year increase.

Additionally, the company raised its full-year revenue guidance to $1.60 billion to $1.61 billion, surpassing the analyst consensus of $1.59 billion. The company also recently announced a roughly $1.5 billion enterprise value acquisition of cancer detection firm Personalis, integrating molecular residual disease testing into its AI-driven precision oncology platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)